Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | ABBV-621 |
Synonyms | |
Therapy Description |
ABBV-621 (eftozanermin alfa) is TRAIL receptor agonist comprising human IgG1-Fc fused to the TRAIL-receptor binding domain, which potentially induces apoptosis and decreases tumor growth (PMID: 35467243, PMID: 33687950). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
ABBV-621 | ABBV621|ABBV 621|eftozanermin alfa|APG880|eftoza | ABBV-621 (eftozanermin alfa) is TRAIL receptor agonist comprising human IgG1-Fc fused to the TRAIL-receptor binding domain, which potentially induces apoptosis and decreases tumor growth (PMID: 35467243, PMID: 33687950). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT03082209 | Phase I | ABBV-621 | A Study of the Safety and Tolerability of ABBV-621 in Participants With Previously Treated Solid Tumors and Hematologic Malignancies | Completed | USA | NLD | ESP | 1 |